Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (221-230 of 461) with videos related to

Pageof 47
Sort By:
Journal of Neuroscience Methods|December 3, 2014
Anatomical landmarks for registration of experimental image data to volumetric rodent brain atlasing templatesMarina Sergejeva, Eszter A Papp, Rembrandt Bakker, et al.
The American Journal of Psychiatry|October 1, 1995
Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disordersL A Papp, J R Weiss, H E Greenberg, et al.
Journal of the American Academy of Dermatology|July 6, 2010
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendationsMark Lebwohl, Newman Yeilding, Philippe Szapary, et al.
BMC Dermatology|May 9, 2015
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasisFernando Valenzuela, Kim A Papp, David Pariser, et al.
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part IIKim A Papp, Charles Camisa, Stephen P Stone, et al.
Biological Psychiatry|August 1, 1992
Exercise tolerance in panic disorder patientsJ M Stein, L A Papp, D F Klein, et al.
The British Journal of Dermatology|July 10, 2019
Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trialA B Gottlieb, A Kubanov, M van Doorn, et al.
JAMA|December 18, 2003
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialKenneth B Gordon, Kim A Papp, Tiffani K Hamilton, et al.
Archives of General Psychiatry|July 1, 1997
Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorderJ D Coplan, L A Papp, D Pine, et al.
Journal of the American Academy of Dermatology|March 22, 2018
Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysisAlice B Gottlieb, Kim A Papp, Charles A Birbara, et al.
Pageof 47

Showing results (221-230 of 461) with videos related to

Sort By:
Pageof 47
Journal of Neuroscience Methods|December 3, 2014
Anatomical landmarks for registration of experimental image data to volumetric rodent brain atlasing templatesMarina Sergejeva, Eszter A Papp, Rembrandt Bakker, et al.
The American Journal of Psychiatry|October 1, 1995
Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disordersL A Papp, J R Weiss, H E Greenberg, et al.
Journal of the American Academy of Dermatology|July 6, 2010
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendationsMark Lebwohl, Newman Yeilding, Philippe Szapary, et al.
BMC Dermatology|May 9, 2015
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasisFernando Valenzuela, Kim A Papp, David Pariser, et al.
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part IIKim A Papp, Charles Camisa, Stephen P Stone, et al.
Biological Psychiatry|August 1, 1992
Exercise tolerance in panic disorder patientsJ M Stein, L A Papp, D F Klein, et al.
The British Journal of Dermatology|July 10, 2019
Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trialA B Gottlieb, A Kubanov, M van Doorn, et al.
JAMA|December 18, 2003
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialKenneth B Gordon, Kim A Papp, Tiffani K Hamilton, et al.
Archives of General Psychiatry|July 1, 1997
Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorderJ D Coplan, L A Papp, D Pine, et al.
Journal of the American Academy of Dermatology|March 22, 2018
Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysisAlice B Gottlieb, Kim A Papp, Charles A Birbara, et al.
Pageof 47